Your Sorted CME/CE Activities


Conversations in HIV: Evolving Treatment Options
Certified CME/CNE/CPE Activity
As therapy and our understanding of the HIV disease process progresses, so do our management approaches, as noted by the multiple updates issued by the DHHS and IAS-USA on their guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Guideline updates such as these have a rapid impact on application to clinical practice, affecting treatment strategies and preferences in HIV patient management. New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of HIV treatment as HIV prevention and development of long-acting novel agents.

This Conversations in HIV will discuss evolving treatment options in HIV, such as the benefits and risks of 2 vs 3 drug therapy, integrase inhibitor vs protease inhibitor use and what’s on the horizon in antiretroviral therapy.
Review each video to claim AMA, ANCC, or ACPE credit/contact hour(s) after completion of the brief Post-Test/Evaluation.





Eric Daar, MD Eric Daar, MD
Interim Chair, Department of Medicine
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Paul Sax, MD Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical Center
       
Babafemi Taiwo, MBBS Babafemi Taiwo, MBBS
Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
   

20
Supported by an independent educational grant from ViiV Healthcare
Expired Activity
Clinical Conversation
6162
ConversationsInHIV_v2_WebBanner1150.gif
HIV